Clinical Trial Design Feasibility Assessment
Systematically assess clinical trial feasibility by analyzing 6 research dimensions. Produces comprehensive feasibility reports with quantitative enrollment projections, endpoint recommendations, and regulatory pathway analysis.
IMPORTANT: Always use English terms in tool calls (drug names, disease names, biomarker names), even if the user writes in another language. Only try original-language terms as a fallback if English returns no results. Respond in the user's language.
Reasoning Before Searching
Trial design starts with the question, not the methods. Answer these four questions before running any tools — they determine everything else:
- What is the primary endpoint? Is it overall survival (gold standard but slow), PFS (faster but surrogate), ORR (single-arm friendly but not always accepted), or a biomarker (needs validation as surrogate first)? The endpoint determines FDA pathway, statistical design, and duration.
- Who is the population? Broad unselected vs. biomarker-enriched. Enriched populations have higher response rates, allowing smaller trials — but require a validated companion diagnostic and reduce the eligible patient pool.
- What is the comparator? Placebo (only if no standard of care exists), active control (requires non-inferiority or superiority framing), or single-arm with historical control (acceptable for rare diseases or breakthrough designations, but FDA scrutiny is high).
- Is the effect size realistic given the mechanism? A 20% improvement in ORR over SOC requires ~100 patients per arm. A 50% improvement requires ~30. If the mechanism only justifies a 10% improvement, the trial may be underpowered regardless of design. Check precedent effect sizes in similar trials before committing to an endpoint.
These four answers determine sample size, duration, and trial design. Look them up from precedent trials and FDA guidance — do not derive them from first principles.
LOOK UP DON'T GUESS: Never assume what the standard of care is for an indication — look it up with DrugBank and FDA tools. Never assume an endpoint is FDA-accepted — verify with search_clinical_trials precedents and OpenFDA_get_approval_history. Never estimate prevalence from memory — use OpenTargets, gnomAD, or COSMIC.
Core Principles
1. Report-First Approach (MANDATORY)
DO NOT show tool outputs to user. Instead:
- Create
[INDICATION]_trial_feasibility_report.md FIRST
- Initialize with all section headers
- Progressively update as data arrives
- Present only the final report
2. Evidence Grading System
| Grade |
Symbol |
Criteria |
Examples |
| A |
3-star |
Regulatory acceptance, multiple precedents |
FDA-approved endpoint in same indication |
| B |
2-star |
Clinical validation, single precedent |
Phase 3 trial in related indication |
| C |
1-star |
Preclinical or exploratory |
Phase 1 use, biomarker validation ongoing |
| D |
0-star |
Proposed, no validation |
Novel endpoint, no precedent |
3. Feasibility Score (0-100)
Weighted composite score:
- Patient Availability (30%): Population size x biomarker prevalence x geography
- Endpoint Precedent (25%): Historical use, regulatory acceptance
- Regulatory Clarity (20%): Pathway defined, precedents exist
- Comparator Feasibility (15%): Standard of care availability
- Safety Monitoring (10%): Known risks, monitoring established
Interpretation: >=75 HIGH (proceed), 50-74 MODERATE (additional validation), <50 LOW (de-risking required)
When to Use This Skill
Apply when users:
- Plan early-phase trials (Phase 1/2 emphasis)
- Need enrollment feasibility assessment
- Design biomarker-selected trials
- Evaluate endpoint strategies
- Assess regulatory pathways
- Compare trial design options
- Need safety monitoring plans
Trigger phrases: "clinical trial design", "trial feasibility", "enrollment projections", "endpoint selection", "trial planning", "Phase 1/2 design", "basket trial", "biomarker trial"
Core Strategy: 6 Research Paths
Execute 6 parallel research dimensions. See STUDY_DESIGN_PROCEDURES.md for detailed steps per path.
Trial Design Query
|
+-- PATH 1: Patient Population Sizing
| Disease prevalence, biomarker prevalence, geographic distribution,
| eligibility criteria impact, enrollment projections
|
+-- PATH 2: Biomarker Prevalence & Testing
| Mutation frequency, testing availability, turnaround time,
| cost/reimbursement, alternative biomarkers
|
+-- PATH 3: Comparator Selection
| Standard of care, approved comparators, historical controls,
| placebo appropriateness, combination therapy
|
+-- PATH 4: Endpoint Selection
| Primary endpoint precedents, FDA acceptance history,
| measurement feasibility, surrogate vs clinical endpoints
|
+-- PATH 5: Safety Endpoints & Monitoring
| Mechanism-based toxicity, class effects, organ-specific monitoring,
| DLT history, safety monitoring plan
|
+-- PATH 6: Regulatory Pathway
Regulatory precedents (505(b)(1), 505(b)(2)), breakthrough therapy,
orphan drug, fast track, FDA guidance
Report Structure (14 Sections)
Create [INDICATION]_trial_feasibility_report.md with all 14 sections. See REPORT_TEMPLATE.md for full templates with fillable fields.
- Executive Summary - Feasibility score, key findings, go/no-go recommendation
- Disease Background - Prevalence, incidence, SOC, unmet need
- Patient Population Analysis - Base population, biomarker selection, eligibility funnel, enrollment projections
- Biomarker Strategy - Primary biomarker, alternatives, testing logistics
- Endpoint Selection & Justification - Primary/secondary/exploratory endpoints, statistical considerations
- Comparator Analysis - SOC, trial design options (single-arm vs randomized vs non-inferiority), drug sourcing
- Safety Endpoints & Monitoring Plan - DLT definition, mechanism-based toxicities, organ monitoring, SMC
- Study Design Recommendations - Phase, design type, schema, eligibility, treatment plan, assessment schedule
- Enrollment & Site Strategy - Site selection, enrollment projections, recruitment strategies
- Regulatory Pathway - FDA pathway, precedents, pre-IND meeting, IND timeline
- Budget & Resource Considerations - Cost drivers, timeline, FTE requirements
- Risk Assessment - Feasibility risks, scientific risks, mitigation strategies
- Success Criteria & Go/No-Go Decision - Phase 1/2 criteria, interim analysis, feasibility scorecard
- Recommendations & Next Steps - Final recommendation, critical path to IND, alternative designs
Tool Reference by Research Path
PATH 1: Patient Population Sizing
OpenTargets_get_disease_id_description_by_name - Disease lookup
OpenTargets_get_diseases_phenotypes_by_target_ensembl - Prevalence data
ClinVar_search_variants - Biomarker mutation frequency
gnomad_search_variants - Population allele frequencies
PubMed_search_articles - Epidemiology literature
search_clinical_trials - Enrollment feasibility from past trials
PATH 2: Biomarker Prevalence & Testing
ClinVar_get_variant_details - Variant pathogenicity
COSMIC_search_mutations - Cancer-specific mutation frequencies
gnomad_get_variant - Population genetics
PubMed_search_articles - CDx test performance, guidelines
PATH 3: Comparator Selection
drugbank_get_drug_basic_info_by_drug_name_or_id - Drug info
drugbank_get_indications_by_drug_name_or_drugbank_id - Approved indications
drugbank_get_pharmacology_by_drug_name_or_drugbank_id - Mechanism
FDA_OrangeBook_search_drug - Generic availability
OpenFDA_get_approval_history - Approval details
search_clinical_trials - Historical control data
PATH 4: Endpoint Selection
search_clinical_trials - Precedent trials, endpoints used
PubMed_search_articles - FDA acceptance history, endpoint validation
OpenFDA_get_approval_history - Approved endpoints by indication
PATH 5: Safety Endpoints & Monitoring
drugbank_get_pharmacology_by_drug_name_or_drugbank_id - Mechanism toxicity
FDA_get_warnings_and_cautions_by_drug_name - FDA black box warnings
FAERS_search_reports_by_drug_and_reaction - Real-world adverse events
FAERS_count_reactions_by_drug_event - AE frequency
FAERS_count_death_related_by_drug - Serious outcomes
PubMed_search_articles - DLT definitions, monitoring strategies
PATH 6: Regulatory Pathway
OpenFDA_get_approval_history - Precedent approvals
PubMed_search_articles - Breakthrough designations, FDA guidance
search_clinical_trials - Regulatory precedents (accelerated approval)
Quick Start Example
from tooluniverse import ToolUniverse
tu = ToolUniverse()
tu.load_tools()
# Example: EGFR+ NSCLC trial feasibility
# Step 1: Disease prevalence
disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(
diseaseName="non-small cell lung cancer"
)
# Returns HPO phenotypes only, not prevalence figures; get prevalence from literature
prevalence = tu.tools.OpenTargets_get_associated_phenotypes_by_disease_efoId(
efoId=disease_info['data']['search']['hits'][0]['id']
)
# Step 2: Biomarker prevalence
variants = tu.tools.ClinVar_search_variants(gene="EGFR", significance="pathogenic")
# Step 3: Precedent trials
trials = tu.tools.ClinicalTrials_search_studies(
condition="EGFR positive non-small cell lung cancer",
filter_status="COMPLETED", filter_phase="PHASE2"
)
# Step 4: Standard of care comparator
soc = tu.tools.FDA_OrangeBook_search_drug(generic_name="osimertinib")
# Compile into feasibility report...
See WORKFLOW_DETAILS.md for the complete 6-path Python workflow and use case examples.
Next Steps
Once this feasibility assessment is complete, use tooluniverse-clinical-trial-protocol to turn the 6-dimension findings (endpoint, population, comparator, effect size, duration, regulatory pathway) into an actual protocol document — full ICH E6(R2)/FDA-style sections plus a real sample-size calculation. That skill consumes this report's output rather than re-deriving feasibility.
Integration with Other Skills
- tooluniverse-drug-research: Investigate mechanism, preclinical data
- tooluniverse-disease-research: Deep dive on disease biology
- tooluniverse-target-research: Validate drug target, essentiality
- tooluniverse-pharmacovigilance: Post-market safety for comparator drugs
- tooluniverse-precision-oncology: Biomarker biology, resistance mechanisms
Programmatic Access (Beyond Tools)
When ToolUniverse tools return limited trial metadata, use the ClinicalTrials.gov v2 API directly:
import requests, pandas as pd
# Search with pagination (all lung cancer immunotherapy trials with results)
all_studies = []
token = None
while True:
params = {"query.cond": "lung cancer", "query.intr": "immunotherapy",
"filter.overallStatus": "COMPLETED", "filter.results": "WITH_RESULTS", "pageSize": 100}
if token: params["pageToken"] = token
resp = requests.get("https://clinicaltrials.gov/api/v2/studies", params=params).json()
all_studies.extend(resp.get("studies", []))
token = resp.get("nextPageToken")
if not token: break
# Extract structured data
rows = []
for s in all_studies:
proto = s.get("protocolSection", {})
rows.append({
"nctId": proto.get("identificationModule", {}).get("nctId"),
"title": proto.get("identificationModule", {}).get("briefTitle"),
"enrollment": proto.get("designModule", {}).get("enrollmentInfo", {}).get("count"),
"phase": proto.get("designModule", {}).get("phases", [None])[0] if proto.get("designModule", {}).get("phases") else None,
})
df = pd.DataFrame(rows)
# FDA drug approval history
drug = "pembrolizumab"
fda = requests.get(f"https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:{drug}&limit=10").json()
See tooluniverse-data-wrangling skill for pagination, error handling, and bulk download patterns.
Reference Files
| File |
Content |
REPORT_TEMPLATE.md |
Full 14-section report template with fillable fields |
STUDY_DESIGN_PROCEDURES.md |
Detailed steps for each of the 6 research paths |
WORKFLOW_DETAILS.md |
Complete Python example workflow and 5 use case summaries |
BEST_PRACTICES.md |
Best practices, common pitfalls, output format requirements |
EXAMPLES.md |
Additional examples |
QUICK_START.md |
Quick start guide |
Version Information
- Version: 1.0.0
- Last Updated: February 2026
- Compatible with: ToolUniverse 0.5+
- Focus: Phase 1/2 early clinical development
1---23name: tooluniverse-clinical-trial-design-24description: "Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math."5metadata:6 source: https://skillmd.com/skills/mims-harvard/tooluniverse-clinical-trial-design-27---89# Clinical Trial Design Feasibility Assessment1011Systematically assess clinical trial feasibility by analyzing 6 research dimensions. Produces comprehensive feasibility reports with quantitative enrollment projections, endpoint recommendations, and regulatory pathway analysis.1213**IMPORTANT**: Always use English terms in tool calls (drug names, disease names, biomarker names), even if the user writes in another language. Only try original-language terms as a fallback if English returns no results. Respond in the user's language.1415## Reasoning Before Searching1617Trial design starts with the question, not the methods. Answer these four questions before running any tools — they determine everything else:18191. **What is the primary endpoint?** Is it overall survival (gold standard but slow), PFS (faster but surrogate), ORR (single-arm friendly but not always accepted), or a biomarker (needs validation as surrogate first)? The endpoint determines FDA pathway, statistical design, and duration.202. **Who is the population?** Broad unselected vs. biomarker-enriched. Enriched populations have higher response rates, allowing smaller trials — but require a validated companion diagnostic and reduce the eligible patient pool.213. **What is the comparator?** Placebo (only if no standard of care exists), active control (requires non-inferiority or superiority framing), or single-arm with historical control (acceptable for rare diseases or breakthrough designations, but FDA scrutiny is high).224. **Is the effect size realistic given the mechanism?** A 20% improvement in ORR over SOC requires ~100 patients per arm. A 50% improvement requires ~30. If the mechanism only justifies a 10% improvement, the trial may be underpowered regardless of design. Check precedent effect sizes in similar trials before committing to an endpoint.2324These four answers determine sample size, duration, and trial design. Look them up from precedent trials and FDA guidance — do not derive them from first principles.2526**LOOK UP DON'T GUESS**: Never assume what the standard of care is for an indication — look it up with DrugBank and FDA tools. Never assume an endpoint is FDA-accepted — verify with `search_clinical_trials` precedents and `OpenFDA_get_approval_history`. Never estimate prevalence from memory — use OpenTargets, gnomAD, or COSMIC.2728## Core Principles2930### 1. Report-First Approach (MANDATORY)31**DO NOT** show tool outputs to user. Instead:321. Create `[INDICATION]_trial_feasibility_report.md` FIRST332. Initialize with all section headers343. Progressively update as data arrives354. Present only the final report3637### 2. Evidence Grading System3839| Grade | Symbol | Criteria | Examples |40|-------|--------|----------|----------|41| **A** | 3-star | Regulatory acceptance, multiple precedents | FDA-approved endpoint in same indication |42| **B** | 2-star | Clinical validation, single precedent | Phase 3 trial in related indication |43| **C** | 1-star | Preclinical or exploratory | Phase 1 use, biomarker validation ongoing |44| **D** | 0-star | Proposed, no validation | Novel endpoint, no precedent |4546### 3. Feasibility Score (0-100)47Weighted composite score:48- **Patient Availability** (30%): Population size x biomarker prevalence x geography49- **Endpoint Precedent** (25%): Historical use, regulatory acceptance50- **Regulatory Clarity** (20%): Pathway defined, precedents exist51- **Comparator Feasibility** (15%): Standard of care availability52- **Safety Monitoring** (10%): Known risks, monitoring established5354**Interpretation**: >=75 HIGH (proceed), 50-74 MODERATE (additional validation), <50 LOW (de-risking required)5556---5758## When to Use This Skill5960Apply when users:61- Plan early-phase trials (Phase 1/2 emphasis)62- Need enrollment feasibility assessment63- Design biomarker-selected trials64- Evaluate endpoint strategies65- Assess regulatory pathways66- Compare trial design options67- Need safety monitoring plans6869**Trigger phrases**: "clinical trial design", "trial feasibility", "enrollment projections", "endpoint selection", "trial planning", "Phase 1/2 design", "basket trial", "biomarker trial"7071---7273## Core Strategy: 6 Research Paths7475Execute 6 parallel research dimensions. See `STUDY_DESIGN_PROCEDURES.md` for detailed steps per path.7677```78Trial Design Query79|80+-- PATH 1: Patient Population Sizing81| Disease prevalence, biomarker prevalence, geographic distribution,82| eligibility criteria impact, enrollment projections83|84+-- PATH 2: Biomarker Prevalence & Testing85| Mutation frequency, testing availability, turnaround time,86| cost/reimbursement, alternative biomarkers87|88+-- PATH 3: Comparator Selection89| Standard of care, approved comparators, historical controls,90| placebo appropriateness, combination therapy91|92+-- PATH 4: Endpoint Selection93| Primary endpoint precedents, FDA acceptance history,94| measurement feasibility, surrogate vs clinical endpoints95|96+-- PATH 5: Safety Endpoints & Monitoring97| Mechanism-based toxicity, class effects, organ-specific monitoring,98| DLT history, safety monitoring plan99|100+-- PATH 6: Regulatory Pathway101 Regulatory precedents (505(b)(1), 505(b)(2)), breakthrough therapy,102 orphan drug, fast track, FDA guidance103```104105---106107## Report Structure (14 Sections)108109Create `[INDICATION]_trial_feasibility_report.md` with all 14 sections. See `REPORT_TEMPLATE.md` for full templates with fillable fields.1101111. **Executive Summary** - Feasibility score, key findings, go/no-go recommendation1122. **Disease Background** - Prevalence, incidence, SOC, unmet need1133. **Patient Population Analysis** - Base population, biomarker selection, eligibility funnel, enrollment projections1144. **Biomarker Strategy** - Primary biomarker, alternatives, testing logistics1155. **Endpoint Selection & Justification** - Primary/secondary/exploratory endpoints, statistical considerations1166. **Comparator Analysis** - SOC, trial design options (single-arm vs randomized vs non-inferiority), drug sourcing1177. **Safety Endpoints & Monitoring Plan** - DLT definition, mechanism-based toxicities, organ monitoring, SMC1188. **Study Design Recommendations** - Phase, design type, schema, eligibility, treatment plan, assessment schedule1199. **Enrollment & Site Strategy** - Site selection, enrollment projections, recruitment strategies12010. **Regulatory Pathway** - FDA pathway, precedents, pre-IND meeting, IND timeline12111. **Budget & Resource Considerations** - Cost drivers, timeline, FTE requirements12212. **Risk Assessment** - Feasibility risks, scientific risks, mitigation strategies12313. **Success Criteria & Go/No-Go Decision** - Phase 1/2 criteria, interim analysis, feasibility scorecard12414. **Recommendations & Next Steps** - Final recommendation, critical path to IND, alternative designs125126---127128## Tool Reference by Research Path129130### PATH 1: Patient Population Sizing131- `OpenTargets_get_disease_id_description_by_name` - Disease lookup132- `OpenTargets_get_diseases_phenotypes_by_target_ensembl` - Prevalence data133- `ClinVar_search_variants` - Biomarker mutation frequency134- `gnomad_search_variants` - Population allele frequencies135- `PubMed_search_articles` - Epidemiology literature136- `search_clinical_trials` - Enrollment feasibility from past trials137138### PATH 2: Biomarker Prevalence & Testing139- `ClinVar_get_variant_details` - Variant pathogenicity140- `COSMIC_search_mutations` - Cancer-specific mutation frequencies141- `gnomad_get_variant` - Population genetics142- `PubMed_search_articles` - CDx test performance, guidelines143144### PATH 3: Comparator Selection145- `drugbank_get_drug_basic_info_by_drug_name_or_id` - Drug info146- `drugbank_get_indications_by_drug_name_or_drugbank_id` - Approved indications147- `drugbank_get_pharmacology_by_drug_name_or_drugbank_id` - Mechanism148- `FDA_OrangeBook_search_drug` - Generic availability149- `OpenFDA_get_approval_history` - Approval details150- `search_clinical_trials` - Historical control data151152### PATH 4: Endpoint Selection153- `search_clinical_trials` - Precedent trials, endpoints used154- `PubMed_search_articles` - FDA acceptance history, endpoint validation155- `OpenFDA_get_approval_history` - Approved endpoints by indication156157### PATH 5: Safety Endpoints & Monitoring158- `drugbank_get_pharmacology_by_drug_name_or_drugbank_id` - Mechanism toxicity159- `FDA_get_warnings_and_cautions_by_drug_name` - FDA black box warnings160- `FAERS_search_reports_by_drug_and_reaction` - Real-world adverse events161- `FAERS_count_reactions_by_drug_event` - AE frequency162- `FAERS_count_death_related_by_drug` - Serious outcomes163- `PubMed_search_articles` - DLT definitions, monitoring strategies164165### PATH 6: Regulatory Pathway166- `OpenFDA_get_approval_history` - Precedent approvals167- `PubMed_search_articles` - Breakthrough designations, FDA guidance168- `search_clinical_trials` - Regulatory precedents (accelerated approval)169170---171172## Quick Start Example173174```python175from tooluniverse import ToolUniverse176177tu = ToolUniverse()178tu.load_tools()179180# Example: EGFR+ NSCLC trial feasibility181# Step 1: Disease prevalence182disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(183 diseaseName="non-small cell lung cancer"184)185# Returns HPO phenotypes only, not prevalence figures; get prevalence from literature186prevalence = tu.tools.OpenTargets_get_associated_phenotypes_by_disease_efoId(187 efoId=disease_info['data']['search']['hits'][0]['id']188)189190# Step 2: Biomarker prevalence191variants = tu.tools.ClinVar_search_variants(gene="EGFR", significance="pathogenic")192193# Step 3: Precedent trials194trials = tu.tools.ClinicalTrials_search_studies(195 condition="EGFR positive non-small cell lung cancer",196 filter_status="COMPLETED", filter_phase="PHASE2"197)198199# Step 4: Standard of care comparator200soc = tu.tools.FDA_OrangeBook_search_drug(generic_name="osimertinib")201202# Compile into feasibility report...203```204205See `WORKFLOW_DETAILS.md` for the complete 6-path Python workflow and use case examples.206207---208209## Next Steps210211Once this feasibility assessment is complete, use **`tooluniverse-clinical-trial-protocol`** to turn the 6-dimension findings (endpoint, population, comparator, effect size, duration, regulatory pathway) into an actual protocol document — full ICH E6(R2)/FDA-style sections plus a real sample-size calculation. That skill consumes this report's output rather than re-deriving feasibility.212213## Integration with Other Skills214215- **tooluniverse-drug-research**: Investigate mechanism, preclinical data216- **tooluniverse-disease-research**: Deep dive on disease biology217- **tooluniverse-target-research**: Validate drug target, essentiality218- **tooluniverse-pharmacovigilance**: Post-market safety for comparator drugs219- **tooluniverse-precision-oncology**: Biomarker biology, resistance mechanisms220221---222223## Programmatic Access (Beyond Tools)224225When ToolUniverse tools return limited trial metadata, use the ClinicalTrials.gov v2 API directly:226227```python228import requests, pandas as pd229230# Search with pagination (all lung cancer immunotherapy trials with results)231all_studies = []232token = None233while True:234 params = {"query.cond": "lung cancer", "query.intr": "immunotherapy",235 "filter.overallStatus": "COMPLETED", "filter.results": "WITH_RESULTS", "pageSize": 100}236 if token: params["pageToken"] = token237 resp = requests.get("https://clinicaltrials.gov/api/v2/studies", params=params).json()238 all_studies.extend(resp.get("studies", []))239 token = resp.get("nextPageToken")240 if not token: break241242# Extract structured data243rows = []244for s in all_studies:245 proto = s.get("protocolSection", {})246 rows.append({247 "nctId": proto.get("identificationModule", {}).get("nctId"),248 "title": proto.get("identificationModule", {}).get("briefTitle"),249 "enrollment": proto.get("designModule", {}).get("enrollmentInfo", {}).get("count"),250 "phase": proto.get("designModule", {}).get("phases", [None])[0] if proto.get("designModule", {}).get("phases") else None,251 })252df = pd.DataFrame(rows)253254# FDA drug approval history255drug = "pembrolizumab"256fda = requests.get(f"https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:{drug}&limit=10").json()257```258259See `tooluniverse-data-wrangling` skill for pagination, error handling, and bulk download patterns.260261---262263## Reference Files264265| File | Content |266|------|---------|267| `REPORT_TEMPLATE.md` | Full 14-section report template with fillable fields |268| `STUDY_DESIGN_PROCEDURES.md` | Detailed steps for each of the 6 research paths |269| `WORKFLOW_DETAILS.md` | Complete Python example workflow and 5 use case summaries |270| `BEST_PRACTICES.md` | Best practices, common pitfalls, output format requirements |271| `EXAMPLES.md` | Additional examples |272| `QUICK_START.md` | Quick start guide |273274---275276## Version Information277278- **Version**: 1.0.0279- **Last Updated**: February 2026280- **Compatible with**: ToolUniverse 0.5+281- **Focus**: Phase 1/2 early clinical development